WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...

Zimbabwe has earned widespread international praise for its achievements in the fight against HIV, with the latest UNAIDS Global AIDS Update 2025 placing the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

Just yesterday, UNICEF released its 2025 Global HIV Estimates — and the numbers are a sobering call to action. While the world has made undeniable progress in reducing HIV infections among children, ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...